Skip to main content
. 2015 Nov 11;26:2520–2528. doi: 10.1007/s00330-015-4074-8

Table 3.

Sensitivity, specificity, positive predictive value of recalls (PPV-1) and invasive procedures (PPV-2) in mammographic screening performed in the US, Norway, and Spain

US Norway Spain
(1996–2008) n =2,656,834 % (95 % CI) (1996–2007) 1,470,854 % (95 % CI) (1996–2009) 1,585,906 % (95 % CI)
Sensitivity 83.1 (82.4 − 83.7) 75.5 (74.7 − 76.4) 79.0 (78.1 − 79.9)
Specificity 91.3 (91.2 − 91.3) 97.1 (97.1 − 97.1) 96.2 (96.2 − 96.2)
PPV-1 4.9 (4.8 − 5.0) 16.4 (16.0 − 16.7) 9.8 (9.8 − 9.8)
1/PPV-1 20.3 (20.0 − 20.7) 6.1 (6.0 − 6.2) 10.2 (10.2 − 10.3)
PPV-2 25.9a (25.4 − 26.4) 39.4 (38.7 − 40.1) 38.9 (38.9 − 38.9)
1/PPV-2 3.9 (3.8 − 3.9) 2.5 ( 2.5 − 2.6) 2.6 (2.6 − 2.6)

aUS data do not capture all biopsies: the number of women who were recommended to receive a biopsy, defined as BI-RADS assessment at the end of all imaging workup of 4 or 5, or BI-RADS assessment of 0 or 3 accompanied by recommendation for biopsy, FNAC, or surgical consult is thus reported